5-Fluorouracil containing combinations in murine tumor systems
- 1 April 1989
- journal article
- review article
- Published by Springer Nature in Investigational New Drugs
- Vol. 7 (1) , 37-49
- https://doi.org/10.1007/bf00178190
Abstract
5-FUra is a familiar member of a variety of clinically useful regimens. Examples include: Cytoxan-Adriamycin-5-FUra (CAP); Methotrexate-Prednisone-Vincristine-Cytoxan-5-FUra (the Cooper regimen); and CisDDPt-5-FUra. In addition to its clinical utility, over 20 different 5-FUra-combinations have been reported to be therapeutically synergistic in experimental systems (Table 1). In this report, we will attempt to evaluate the reasons behind the widespread utility of this agent in combination therapy and suggest future directions for research efforts.Keywords
This publication has 24 references indexed in Scilit:
- Is the P388 murine tumor no longer adequate as a drug discovery model?Investigational New Drugs, 1987
- Activity of flavone acetic acid (NSC-347512) against solid tumors of miceInvestigational New Drugs, 1986
- Correlations between anthracycline resistance, drug accumulation and membrane glycoprotein patterns in solid tumors of miceCancer Letters, 1985
- Establishment of cross-resistance profiles for new agents.1983
- Cross resistance between actinomycin-D, adriamycin and vincristine in a murine solid tumour in vivoBiochemical Pharmacology, 1980
- Uptake and binding of vincristine by murine leukemia cellsBiochemical Pharmacology, 1975
- Fluorinated Pyrimidines and Their NucleosidesPublished by Springer Nature ,1975
- SOME BIOCHEMICAL PROPERTIES OF CHINESE HAMSTER CELLS SENSITIVE AND RESISTANT TO ACTINOMYCIN DThe Journal of cell biology, 1974
- Mechanism of Cellular Drug ResistanceNature, 1971
- Drug Synergism in Antineoplastic ChemotherapyPublished by Elsevier ,1964